A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

Inclusion Criteria: * Informed Consent * 18 - 65 years * Positive for HSV-1 and/or -2 (as determined by serology testing in course of study) * Initial infection \> 1 year ago * ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy) * ≥ 2 recurrences during the six-month baseline period Exclusion Criteria: * Known or suspected allergy or intolerability to PEG * Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial * Pregnancy and/or breast-feeding * History of malignant diseases (described in chapter 7.2) * Known or suspected non-compliance to study protocol * Participation in another investigational drug study in the last 30 days prior to baseline period